CORT
Corcept Therapeutics Incorporated
$79.94
-$0.58(-0.72%)
40
Overall
20
Value
60
Tech
--
Quality
Market Cap
$7.52B
Volume
540.56K
52W Range
$41.92 - $117.33
Target Price
$135.25
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $50.3M | $81.3M | $159.2M | $251.2M | $306.5M | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | ||
| Total Revenue | $50.3M | $81.3M | $159.2M | $251.2M | $306.5M | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-1.4M | $-2.1M | $-3.6M | $-5.2M | $5.5M | $5.6M | $5.3M | $5.4M | $6.5M | $10.9M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $48.9M | $79.3M | $155.6M | $246.0M | $301.0M | $348.3M | $360.7M | $396.5M | $475.9M | $664.2M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $52.4M | $69.1M | $102.8M | $156.5M | $189.4M | $220.1M | $236.2M | $283.8M | $368.6M | $527.2M | ||
| Research & Development | $15.4M | $23.8M | $40.4M | $75.2M | $89.0M | $114.8M | $113.9M | $131.0M | $184.4M | $246.9M | ||
| Research Expense | $15.4M | $23.8M | $40.4M | $75.2M | $89.0M | $114.8M | $113.9M | $131.0M | $184.4M | $246.9M | ||
| Selling, General & Administrative | $36.9M | $45.2M | $62.4M | $81.3M | $100.4M | $105.3M | $122.4M | $152.8M | $184.3M | $280.3M | ||
| Selling & Marketing Expenses | $36.9M | $45.2M | $62.4M | $81.3M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-678.0K | $-900.0K | $-1.1M | $-1.3M | $100.4M | $105.3M | $122.4M | $152.8M | $184.3M | $280.3M | ||
| Salaries & Wages | $-6.0M | $-7.1M | $-13.4M | $-23.8M | $29.4M | $33.8M | $43.2M | -- | -- | -- | ||
| Other Operating Expenses | $-169.0K | $-152.0K | $-20.7M | $-752.0K | $-1.0M | $-1.3M | $-1.7M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-3.4M | $10.2M | $52.9M | $89.5M | $111.6M | $128.2M | $124.5M | $112.6M | $107.3M | $137.0M | ||
| EBITDA | $-6.2M | $8.2M | $52.9M | $92.4M | $118.8M | $130.4M | $128.0M | $119.6M | $126.9M | $162.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Income Operating | -- | -- | -- | $2.7M | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-3.0M | $-2.0M | $-49.0K | -- | -- | -- | -- | $-3.6M | $-17.3M | -- | ||
| Gain on Sale of Securities | -- | -- | $-49.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | -- | $2.0M | $-15.7M | $-29.3M | $-28.1M | $-26.5M | $-31.4M | $-3.6M | $-17.3M | $-24.5M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | -- | $3.6M | $17.3M | $24.5M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-2.8M | $-1.9M | $-500.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $2.8M | $1.9M | $500.0K | $2.7M | -- | -- | -- | $14.0M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-6.4M | $8.1M | $52.8M | $92.2M | $116.7M | $128.2M | $124.5M | $116.2M | $124.6M | $161.5M | ||
| Pre-Tax Income | $-6.4M | $8.1M | $52.8M | $92.2M | $116.7M | $131.6M | $125.0M | $116.2M | $124.6M | $161.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $-76.3M | $16.7M | $22.5M | $25.6M | $12.5M | $14.8M | $18.4M | $20.3M | ||
| NET INCOME | ||||||||||||
| Net Income | $-6.4M | $8.1M | $129.1M | $75.4M | $94.2M | $106.0M | $112.5M | $101.4M | $106.1M | $141.2M | ||
| Net Income (Continuing Operations) | $-6.4M | $8.1M | $129.1M | $75.4M | $94.2M | $106.0M | $112.5M | $101.4M | $106.1M | $141.2M | ||
| Net Income (Discontinued Operations) | $-6.4M | $8.1M | $129.1M | $75.4M | $94.2M | $106.0M | $112.5M | $101.4M | $106.1M | $141.2M | ||
| Net Income (Common Stockholders) | $-6.4M | $8.1M | $129.1M | $75.4M | $89.1M | $106.0M | $112.5M | $101.3M | $105.5M | $139.7M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $159.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $51.0M | $67.0M | $99.2M | $151.3M | $194.9M | $225.7M | $241.5M | $289.2M | $375.1M | $538.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $106.9M | $110.6M | $113.5M | $115.3M | $114.3M | $115.4M | $115.7M | $106.8M | $103.6M | $103.2M | ||
| Average Shares Outstanding (Diluted) | $106.9M | $116.1M | $124.5M | $126.7M | $122.6M | $124.2M | $126.0M | $116.0M | $111.7M | $113.5M | ||
| Shares Outstanding | $109.7M | $112.9M | $114.8M | $114.7M | $114.6M | $117.3M | $105.4M | $107.9M | $103.5M | $105.5M | ||
| Basic EPS | -- | $0.07 | $1.14 | $0.65 | $0.82 | $0.92 | $0.97 | $0.95 | $1.02 | $1.35 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $0.82 | $0.92 | $0.97 | $0.95 | $1.02 | $1.35 | ||
| Diluted EPS | $-0.06 | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $-112.5M | $-101.3M | $-105.5M | $-139.7M | ||
| Acquired In Process Rn D | -- | -- | -- | $2.7M | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-678.0K | $-900.0K | $-1.1M | $-1.3M | $100.4M | $105.3M | $122.4M | $152.8M | $184.3M | $280.3M | ||
| Other Write Off | -- | -- | $-15.7M | $-29.3M | $-28.1M | $-26.5M | $-31.4M | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | -- | -- | -- | $-112.5M | $-101.3M | $-105.5M | $-139.7M | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $-112.5M | $-101.3M | $-105.5M | $-139.7M | ||
| Rent And Landing Fees | $-678.0K | $-900.0K | $-1.1M | $-1.3M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $36.9M | $45.2M | $62.4M | $81.3M | -- | -- | -- | -- | -- | -- | ||
| Restruct | $-2.8M | $-1.9M | $-500.0K | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CORT | $79.94 | -0.7% | 540.56K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Corcept Therapeutics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW